Fig. 1
From: Triple negative breast cancer metastasis is hindered by a peptide antagonist of F11R/JAM‑A protein
The results of in silico analyses. (A) The pan-cancer analysis performed by the web tool TNMplot (https://tnmplot.com/analysis/), showing the expression range for F11R gene across all tissues in all available normal (non-cancerous) and tumor RNA-Seq data. Statistically significant differences by Mann–Whitney U test are marked with red colour and asterisk. AML acute myeloid leukemia, Lung_AC lung adenocarcinoma, Lung_SC lung squamous cell carcinoma, Renal_CC renal clear cell carcinoma, Renal_CH renal chromophobe cell carcinoma, Renal_PA renal papillary cell carcinoma, Uterus_CS uterine carcinosarcoma, Uterus_EC uterine corpus endometrial carcinoma. B Differential F11R gene expression analysis in breast invasive carcinoma performed by TNMplot using RNA-Seq based data from normal and tumour tissues, including paired tumour and adjacent non-cancerous tissues (n = 112). C. The UALCAN (The University of Alabama at Birmingham Cancer data analysis Portal) Resource analysis on samples from The Cancer Genome Atlas (TCGA), presenting the expression of F11R/JAM-A in breast cancer major subclasses of breast invasive carcinoma (BRCA). D Kaplan–Meier plot for F11R gene expression in Triple Negative Breast Cancer (TNBC) based on Gene Expression Omnibus (GEO), European Genome-phenome Archive (EGA), and The Cancer Genome Atlas (TCGA) databases to assess the overall survival (OS) probability. P = 0.0184